2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial

摘要: ResultsIn a pre-clinical humanized OC mouse model, DCP-001 vaccination led to significant reduction of tumor growth rate resulting in partial and complete tumor regressions. In patients, DCP-001 vaccination was well-tolerated and DCP-001 related adverse events were only mild to moderate and mostly related to local injection site reactions. Patients reported fatigue, diarrhea, headache, nausea, temperature elevation and generalized joint and muscle pain. No severe adverse events were observed.ConclusionPre-clinical data in humanized OC mice demonstrated that DCP-001 reduces tumor growth and provided a rational for clinical therapeutic exploitation in OC patients. Initial data from the phase I trial demonstrates that DCP-001 is safe and well-tolerated and justifies continued exploration of this novel immunotherapy concept in OC patients.